IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1000.00 SEK | -99.97% |
| 2022 | 3.69 Million SEK | 47.15% |
| 2021 | 2.5 Million SEK | 24.27% |
| 2020 | 2.01 Million SEK | 0.0% |
| 2019 | - SEK | -100.0% |
| 2018 | 1.67 Million SEK | 191.96% |
| 2017 | -1.81 Million SEK | -48.61% |
| 2016 | -1.22 Million SEK | -76.08% |
| 2015 | -694 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - SEK | -100.0% |
| 2024 Q2 | -65.11 Million SEK | 0.0% |
| 2024 Q3 | - SEK | 100.0% |
| 2023 Q3 | 1.00 SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q4 | 1000.00 SEK | 99900.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 FY | 1000.00 SEK | -99.97% |
| 2022 Q1 | -16.41 Million SEK | 0.0% |
| 2022 Q3 | -21.01 Million SEK | 9.79% |
| 2022 FY | 3.69 Million SEK | 47.15% |
| 2022 Q4 | 3.69 Million SEK | 117.57% |
| 2022 Q2 | -23.29 Million SEK | -41.88% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 FY | 2.5 Million SEK | 24.27% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2020 Q2 | -7.11 Million SEK | -13.72% |
| 2020 FY | 2.01 Million SEK | 0.0% |
| 2020 Q4 | - SEK | 100.0% |
| 2020 Q3 | -8.25 Million SEK | -16.12% |
| 2020 Q1 | -6.25 Million SEK | 0.0% |
| 2019 FY | - SEK | -100.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 100.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | 1.67 Million SEK | 191.96% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 100.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 FY | -1.81 Million SEK | -48.61% |
| 2017 Q1 | -2.75 Million SEK | 0.0% |
| 2017 Q2 | -2.19 Million SEK | 20.56% |
| 2017 Q3 | -3.88 Million SEK | -77.18% |
| 2017 Q4 | -19 Thousand SEK | 99.51% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | -1.22 Million SEK | -76.08% |
| 2016 Q4 | - SEK | 0.0% |
| 2015 FY | -694 Thousand SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -49900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 100.024% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 100.014% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 99.993% |
| Intervacc AB (publ) | 10.48 Million SEK | 99.99% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 140.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 99.997% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 99.989% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 151.282% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 99.968% |
| Saniona AB (publ) | 1.00 SEK | -99900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 100.062% |
| Biovica International AB (publ) | 2.19 Million SEK | 99.955% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -99900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | 99.952% |
| Xintela AB (publ) | 398 Thousand SEK | 99.749% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 99.857% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 100.116% |
| Amniotics AB (publ) | 534 Thousand SEK | 99.813% |
| 2cureX AB (publ) | -1000.00 SEK | 200.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 100.056% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 99.995% |
| Camurus AB (publ) | 100.95 Million SEK | 99.999% |
| Corline Biomedical AB | -3.85 Million SEK | 100.026% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | 99.977% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 99.99% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 100.02% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | 99.817% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 99.998% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 100.224% |
| Nanologica AB (publ) | 2.97 Million SEK | 99.966% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 100.311% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 99.992% |
| Alzinova AB (publ) | -3.27 Million SEK | 100.031% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 99.959% |
| Pila Pharma AB (publ) | 1.00 SEK | -99900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 167.295% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 99.975% |
| Simris Alg AB (publ) | 1.09 Million SEK | 99.908% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 99.996% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 99.999% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 99.903% |